GSK_ Annual_Report_2021-22

153 Notes to the Standalone Financial Statements for the year ended March 31, 2022 Note 50 : Financial instruments - Fair value and Risk Management A. Accounting classification and fair values The following table shows the carrying amounts and fair values of financial assets and financial liabilities including their levels presented below. ( ` in lakhs) As at March 31, 2022 As at March 31, 2021 Financial assets at amortised cost * Security Deposits 6,94.06 8,06.08 Margin money/ Deposit against bank guarantee 4,10.78 4,01.47 Loans to related parties 204,60.00 - Trade receivables 205,23.89 215,60.46 Cash and cash equivalents 280,79.12 404,90.20 Bank balances other than Cash and cash equivalents 2198,32.07 752,77.48 Interest accrued on deposits with bank 7,62.86 7,50.06 Receivable from group companies 55,11.32 11,38.56 Advances recoverable 31.65 31.65 Total financial assets 2963,05.75 1404,55.96 *Excludes investments in subsidiary ( ` in lakhs) As at March 31, 2022 As at March 31, 2021 Financial assets at Fair value through profit and loss Current Investments 365,59.23 - 365,59.23 - ( ` in lakhs) As at March 31, 2022 As at March 31, 2021 Financial liabilities at amortised cost Borrowings - 2.40 Other financial lease liabilities 20,07.65 34,60.26 Security deposits received 2,04.46 2,04.46 Payable to employees 95,49.35 126,97.57 Unclaimed dividends 18,28.05 19,86.36 Trade payables 546,62.95 447,98.85 Creditors for capital goods 1,66.54 2,17.03 Rationalisation relating to a manufacturing site 1,30.28 1,30.28 Other Payables 16,76.35 21,56.59 Total financial liabilities 702,25.63 656,53.80